Page 3 - Eric Elenko News Today

Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12-month price […]

Artia Global Partners LP purchased a new stake in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 99,267 shares of the company’s stock, valued at approximately $19,506,000. Karuna Therapeutics comprises about 7.4% of […]

First Light Asset Management LLC lowered its stake in Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) by 1.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 164,615 shares of the company’s stock after selling 1,701 shares during the period. Karuna Therapeutics accounts for about 3.0% of First Light Asset Management LLC’s holdings, making […]

58.com reissued their maintains rating on shares of Karuna Therapeutics (NASDAQ:KRTX – Get Rating) in a research report released on Monday morning, Benzinga reports. Several other equities research analysts have also commented on the company. HC Wainwright reduced their price objective on Karuna Therapeutics from $320.00 to $300.00 and set a buy rating for the […]

Karuna Therapeutics (NASDAQ:KRTX – Get Rating) had its target price trimmed by JPMorgan Chase & Co. from $260.00 to $250.00 in a report issued on Monday morning, The Fly reports. A number of other brokerages have also recently issued reports on KRTX. Mizuho increased their price objective on Karuna Therapeutics from $270.00 to $274.00 in […]

Karuna Therapeutics (NASDAQ:KRTX – Get Rating) had its price target decreased by JPMorgan Chase & Co. from $260.00 to $250.00 in a research report sent to investors on Monday, The Fly reports. Other equities analysts have also issued reports about the company. Wedbush restated an outperform rating on shares of Karuna Therapeutics in a research […]

Karuna Therapeutics (NASDAQ:KRTX – Get Rating) had its target price reduced by JPMorgan Chase & Co. from $260.00 to $250.00 in a report published on Monday, The Fly reports. Other equities analysts also recently issued research reports about the company. Wedbush reiterated an outperform rating on shares of Karuna Therapeutics in a research report on […]

Karuna Therapeutics (NASDAQ:KRTX – Get Rating)‘s stock had its “maintains” rating reaffirmed by equities research analysts at 58.com in a report released on Monday, Benzinga reports. A number of other analysts have also recently commented on the company. Wedbush reiterated an “outperform” rating on shares of Karuna Therapeutics in a research report on Tuesday, March […]

Sectoral Asset Management Inc. boosted its stake in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) by 12.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,810 shares of the company’s stock after buying an additional 2,500 shares during the […]

Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) have been given a consensus rating of “Moderate Buy” by the sixteen analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 […]